Vape Holdings Inc. (fka VAPE)

[VapeTech]

VAPE Holdings Files for Additional Cannabis-Derived Patent Rights
Accesswire

NG 200 Series Patent Application Focuses on High-Value Biomedical Applications

CHATSWORTH, CA / ACCESSWIRE / May 19, 2015 / VAPE Holdings, Inc. (VAPE) (the "Company" or "VAPE"), a holding company focused on providing healthy, efficient, and sustainable products to lawfully operating participants in the legal cannabis industry, is pleased to announce that it has filed a second application with the US Patent and Trademark Office ("USPTO") for a new class of cannabis-derived products for high-value bio-medical applications. VAPE has designated its new biomedical patent application, and all of its subparts, as the "NG 200 Series Patents."

"Our filing with the USPTO expands VAPE's intellectual property portfolio to include new, high-value cannabis-derived materials and products for the biomedical field," according to VAPE Holdings Chief Executive Officer Kyle Tracey. "The VAPE NG 200 Series Patent applications that we have announced today represent another exciting step forward in our expansion into proprietary, next generation technology," Tracey remarked.

"This patent application is for processes and methods of delivering specific cannabinoid formulations in treatment of a wide range of diseases and medical conditions," explained VAPE Holdings Chief Science Officer Dr. Mark Scialdone. "Our expectation is that our innovations will be of particular interest to the medical community in the treatment of conditions in which successful therapeutic outcome is dependent on localized control of inflammation and pain," added Dr. Scialdone.

With the worldwide market for bio-medical materials in excess of 3 billion dollars, and with attractive growth rates between 10-15%, there exists a considerable opportunity to meet the increasing demand that modern healthcare demands for medical devices and drug delivery formulations.

With its initial patent filing complete, the VAPE team will focus on relatively low cost pre-clinical testing to demonstrate efficacy and safety of preferred delivery methods. VAPE seeks to monetize its NG 200 Series Patents through licensing and partnering relationships with one or more of the increasing number of pharmaceutical companies and medical device companies that are engaged in product development in the legal cannabis space.

About Vape Holdings, Inc.

VAPE Holdings, Inc. focuses on designing, marketing, and distributing various vaporization products and provides management, consulting, branding, real estate and compliant packaging solutions to lawfully operating participants in the legal cannabis industry. The company offers medical and food grade ceramic products primarily under the HIVE Ceramics brand throughout North America, Europe and South America. HIVE offers a nonporous, non-corrosive, chemically inert ceramic vaporization element, which can be used for a range of applications, including stand-alone vaporization products and electronic cigarettes. The company is based in Chatsworth, California.

For more information on HIVE Ceramics and to visit our e-commerce site, please visit:http://www.hiveceramics.com

From time to time, VAPE Holdings will provide market updates and news via its websitehttp://www.vapeholdings.com/ or the Company's Facebook page at http://on.fb.me/1d5c7iO